EOCN

Eocene Ltd

3.10

Oct 30 • 4:00 PM ET 0.00 (0.00%)

Healthcare Biotechnology Israel Nano NASD

Peers: CLDI CVKD HCWB MBIO SXTP MDGL SKYE ALT VKTX LXRX

Index	-
Market Cap	3.23M
Enterprise Value	-8.03M
Income	-11.34M
Sales	0.00M
Book/sh	12.72
Cash/sh	10.93
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	6
IPO	Mar 13, 2014

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.24
P/C	0.28
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	4.16
Current Ratio	4.16
Debt/Eq	0.01
LT Debt/Eq	0.00
Option/Short	No / Yes

EPS (ttm)	-13.81
EPS next Y	-
EPS next Q	-
EPS this Y	-
EPS next Y	-
EPS next 5Y	-
EPS past 3/5Y	73.46% 60.33%
Sales past 3/5Y	- -
EPS Y/Y TTM	68.55%
Sales Y/Y TTM	-
EPS Q/Q	43.43%
Sales Q/Q	-
Earnings	Jul 30
EPS/Sales Surpr.	8.33% -

Insider Own	2.43%
Insider Trans	0.00%
Inst Own	3.95%
Inst Trans	0.26%
ROA	-55.03%
ROE	-68.21%
ROIC	-88.73%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-2.54%
SMA50	-13.29%
SMA200	-32.43%
Trades

Shs Outstand	1.04M
Shs Float	1.02M
Short Float	0.74%
Short Ratio	0.31
Short Interest	0.01M
52W High	12.32 -74.84%
52W Low	2.33 33.05%
Volatility	8.10% 9.41%
ATR (14)	0.30
RSI (14)	43.24
Beta	0.70
Rel Volume	0.00
Avg Volume	24.36K
Volume	0

Perf Week	2.31%
Perf Month	-8.96%
Perf Quarter	-33.76%
Perf Half Y	-32.15%
Perf YTD	-48.37%
Perf Year	-71.08%
Perf 3Y	-91.14%
Perf 5Y	-99.91%
Perf 10Y	-99.94%
Recom	1.00
Target Price	96.00
Prev Close	3.10
Price	3.10
Change %	0.00%

Consensus

Strong Buy

Avg. Price Target

$96.00

Implied Upside

+2,996.8%

Analysts9incl. previous ratings

Rating Distribution8 Buy · 1 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 22, 2020	Downgrade	BB. Riley FBR	Buy → Neutral	$11 → $8	+158.1%
Feb 04, 2020	Initiated	CCraig Hallum	Buy	$18	+480.6%
Jan 30, 2020	Resumed	CCantor Fitzgerald	Overweight	$9 → $14	+351.6%
Dec 02, 2019	Initiated	CCanaccord Genuity	Buy
Dec 12, 2018	Initiated	BB. Riley FBR	Buy	$28	+803.2%
Aug 02, 2018	Reiterated	MMaxim Group	Buy	$30 → $27	+771.0%
Jul 13, 2018	Initiated	SStifel	Buy	$35	+1,029.0%
Jul 12, 2018	Initiated	CCantor Fitzgerald	Overweight	$59	+1,803.2%
Jun 12, 2018	Reiterated	HH.C. Wainwright	Buy	$24 → $43	+1,287.1%
Mar 15, 2018	Upgrade	MMaxim Group	Hold → Buy	$14	+351.6%
Feb 14, 2018	Downgrade	MMaxim Group	Buy → Hold
Feb 12, 2018	Reiterated	HH.C. Wainwright	Buy	$18 → $24	+674.2%
Nov 15, 2017	Initiated	RROTH Capital	Buy	$32	+932.3%
Aug 08, 2017	Reiterated	HH.C. Wainwright	Buy	$12 → $18	+480.6%
Jul 31, 2017	Reiterated	MMaxim Group	Buy	$9 → $14	+351.6%
Aug 01, 2016	Reiterated	MMaxim Group	Buy	$24 → $9	+190.3%
Jul 06, 2016	Resumed	RROTH Capital	Buy	$6	+93.5%
Mar 28, 2016	Resumed	HH.C. Wainwright	Buy	$22	+609.7%
Jun 23, 2015	Initiated	HH.C. Wainwright	Buy	$21	+577.4%
May 06, 2015	Initiated	SSun Trust Rbsn Humphrey	Buy	$20	+545.2%

Sep-09-26 07:30AM	Galmed Pharmaceuticals Becomes EoCene, Unveiling New Ticker Symbol "EOCN" to Reflect its New Dawn Platform for GI Innovation (PR Newswire) +21.05%
Sep-03-26 11:52AM	Galmed Pharmaceuticals: Q2 Earnings Snapshot (Associated Press)
Aug-19-26 07:00AM	Galmed Announces Successful First-in-Human Proof-of-Concept Clinical Study Results for Colospan's Novel Intraoperative Tissue Assessment Technology (PR Newswire) +6.44%
Aug-17-26 09:15AM	Galmed Announces First Time Results in Prostate Oncology Studies: Aramchol Demonstrates 3-4 Fold Increase in Cell Death Compared to Enzalutamide (XTANDI) Alone in Prostate Cancer Models (PR Newswire)
Jul-28-26 07:00AM	Galmed Announces Breakthrough Development of Dispersible Film Delivery (ODF), Brain Penetrating formulation of its SCD1 inhibitor Aramchol for Parkinson's Disease, Targeting $6 Billion Market (PR Newswire)
10:05AM	Loading…
Jul-16-26 10:05AM	Galmed Develops Cardiac-Targeted Aramchol Formulation to Expand Cardiovascular Pipeline (NASDAQ:GLMD) (InvestorsHub) +7.13%
07:30AM	Galmed Announces the Breakthrough Development of Novel LNP Cardiac Targeted Formulation of its SCD1 inhibitor, Aramchol (PR Newswire)
Jun-22-26 07:00AM	Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms for Colospan Ltd., Prioritizing CG-100 European Commercialization and Shareholder Value Protection and Consummation of Acquisition (PR Newswire)
Jun-08-26 08:10AM	Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market (PR Newswire) -32.57%
Jun-02-26 07:30AM	Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis (PR Newswire)
May-14-26 07:30AM	Galmed Announces Results from First-in-Man Pharmacokinetics Study of Oral Formulation of Aramchol Meglumine (AM); 400mg AM Increases Bioavailability by ~500% in Comparison to Aramchol Free Acid (AA) 300mg (PR Newswire) +10.62%
May-06-26 07:30AM	Tissue Dynamics and Galmed Pharmaceuticals to Develop Human-Centered Chronic Cardiac Fibrosis Platform to Advance Aramchol-Based Therapeutics (PR Newswire) +6.41%
Apr-14-26 07:30AM	Galmed Announces a Collaboration Agreement with Tel Aviv University to Evaluate its SCD1 inhibitor, Aramchol, as a Targeted Therapy for Metastatic Brain Cancers (PR Newswire) -6.70%
Apr-09-26 10:30AM	BC-Most Active Stocks (Associated Press) +26.15%
07:30AM	Galmed Announces the Breakthrough Development of a Brain Penetrating New Formulation of its SCD1 inhibitor, Aramchol (PR Newswire)
04:15PM	Loading…
Mar-31-26 04:15PM	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2025 (PR Newswire) +8.16%
Jan-30-26 04:15PM	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire) -5.33% -6.28%
Dec-08-25 08:30AM	Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting (PR Newswire) +8.04%
Dec-04-25 08:30AM	Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH (PR Newswire) +5.61%
Dec-01-25 08:30AM	Galmed Issues CEO Letter to Shareholders (PR Newswire)
Nov-26-25 08:56AM	Galmed Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) +12.40%
08:30AM	Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Nov-18-25 08:30AM	Galmed Announces Meaningful Top Line Results from AM-001 Study of Aramchol Meglumine (PR Newswire)
Nov-17-25 08:30AM	Galmed Announces Top-line Results in Oncology MoA Studies: A 3-drug combination of Aramchol, Stivarga and Metformin Significantly Enhanced GI Tumor Cells, Killing In-vivo and In-vitro (PR Newswire)
Aug-28-25 08:08AM	Galmed Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance)
08:00AM	Galmed Pharmaceuticals Reports Second Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
Aug-25-25 07:30AM	Galmed Announces Digital Asset Management Strategy to Enhance Capital Efficiency and Drive Shareholder Value (PR Newswire) -5.37%
May-27-25 08:00AM	Galmed Identifies Proprietary Biomarker Signature for Aramchol, Unlocking Multi-Billion-Dollar Expansion Potential Beyond NASH (PR Newswire) +6.47%
May-22-25 08:04AM	Galmed Pharmaceuticals: Q1 Earnings Snapshot (Associated Press Finance)
08:00AM	Galmed Pharmaceuticals Reports First Quarter 2025 Financial Results and Provides Business Update (PR Newswire)
08:00AM	Loading…
May-13-25 08:00AM	Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in PSC Models (PR Newswire)
May-10-25 11:55AM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
May-06-25 07:30AM	Galmed Announces First Time Results in Oncology Studies: Aramchol Significantly Enhances Bayer's Regorafenib Effect in GI Cancer Models (PR Newswire) +10.61%
May-01-25 12:15PM	Biotech Alert: Searches spiking for these stocks today (TipRanks)
Apr-28-25 08:00AM	Galmed Signed Term Sheet for the Development of Novel Semaglutide Sublingual Formulation (PR Newswire) +6.37%
Apr-17-25 08:30AM	Galmed Pharmaceuticals Launches VCU Collaboration to Tackle Drug Resistance in GI Cancers (PR Newswire)
Apr-15-25 08:30AM	Galmed Unveils Novel Pharmacodynamic Blood Markers for Aramchol, the Most Clinically Advanced SCD1 Inhibitor (PR Newswire) +6.02%
Apr-10-25 08:00AM	Galmed Announces Positive Part 1 Results from the AM-001 Study of Aramchol Meglumine, an Enhanced Formulation of the Most Clinically Advanced SCD1 Inhibitor (PR Newswire) -11.27%
Apr-02-25 04:10PM	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2024 (PR Newswire) +5.63%
Mar-20-25 08:55AM	Galmed Pharmaceuticals Secures New Patent Grant Extending Aramchol's Patent Protection to 2039, Strengthening Leadership in NASH/MASH Combination Therapy (PR Newswire)
Nov-15-24 08:29AM	Galmed Pharmaceuticals: Q3 Earnings Snapshot (Associated Press Finance) -5.48%
Sep-25-24 08:00AM	Galmed publishes Results from Aramchol Phase 3 Open Label part in Hepatology (PR Newswire) -11.93%
Sep-20-24 09:00AM	How Critical Demand for Metastatic Breast Cancer Therapies is Producing a Multi-Billion Dollar Opportunity for Biotechs (GlobeNewswire) +11.31%
Sep-19-24 07:00AM	Galmed Announces an Expansion of its Activities to Cancer and major Cardiometabolic Diseases (PR Newswire) +21.74%
Jun-22-24 09:52AM	GLMD Stock Earnings: Galmed Pharmaceuticals Reported Results for Q1 2024 (InvestorPlace)
Apr-10-24 06:30AM	Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024 (InvestorPlace)
Apr-05-24 09:53AM	GLMD Stock Earnings: Galmed Pharmaceuticals Misses EPS for Q4 2023 (InvestorPlace)
Apr-04-24 05:06PM	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2023 (PR Newswire)
Mar-15-24 09:00AM	Galmed Announces Grant of New Patent for the Combination of Aramchol with Resmetirom (MGL-3196, REZDIFFRA) for the Treatment of NASH and Liver Fibrosis (PR Newswire) -12.58%
Nov-21-23 07:32AM	Todays Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday (InvestorPlace) -17.08%
Nov-20-23 04:32PM	Galmed Announces a delay in the initiation of its Primary Sclerosing Cholangitis (PSC) Phase 2a Study (PR Newswire) +6.68%
Sep-26-23 08:30AM	Galmed Announces Allowance of New Patent for Aramchol for the Treatment of Pulmonary and Dermal Fibrosis (PR Newswire)
Sep-22-23 04:05PM	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire) +5.00% -6.35%
Aug-10-23 11:08AM	Galmed Pharmaceuticals: Q2 Earnings Snapshot (Associated Press Finance) -7.17%
Jul-14-23 09:20AM	Galmed Pharmaceuticals Announces Pricing of $7 Million Public Offering (PR Newswire) -30.29%
Jul-10-23 08:00AM	Galmed to employ OnKai's disruptive Artificial Intelligence (AI) in its Planned Phase 2a Clinical Trial in PSC (PR Newswire)
Jun-01-23 08:05AM	Galmed Pharmaceuticals: Q1 Earnings Snapshot (AP Finance)
08:00AM	Galmed Pharmaceuticals Reports First Quarter 2023 Financial Results and Recent Developments (PR Newswire)
May-09-23 07:00AM	Galmed Announces Initiation of a Clinical Development Program to Evaluate Aramchol meglumine for the Treatment of Primary Sclerosing Cholangitis (PSC) (PR Newswire)
May-04-23 04:00PM	Galmed Pharmaceuticals forms a Strategic Partnership with OnKai (PR Newswire) +36.16%
Mar-29-23 05:00PM	Galmed Pharmaceuticals Ltd. Files Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2022 (PR Newswire)
Feb-08-23 08:00AM	Galmed Announces Issuance of New Composition of Matter Patent for Aramchol meglumine Salt (PR Newswire)
Jan-06-23 06:34AM	Can Galmed Pharmaceuticals (NASDAQ:GLMD) Afford To Invest In Growth? (Simply Wall St.)
Jan-04-23 08:00AM	Galmed reports results from the Open-Label part of the ARMOR study showing improvements in histology, imaging, and biomarkers with Aramchol (PR Newswire) +9.26%
Dec-14-22 05:00PM	Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) Announces Receipt of Extension to Meet the Nasdaq's Minimum Bid Price Requirement (PR Newswire)
Sep-14-22 12:00PM	Galmed Pharmaceuticals (GLMD) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Aug-04-22 08:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2022 Financial Results (PR Newswire) -9.52%
Jul-18-22 11:43AM	Endo (ENDP) Inks Deal to Develop Rare Disease Drug in Canada (Zacks)
Jul-13-22 10:53AM	Aldeyra's (ALDX) Dry Eye Disease Chamber Study Meets Goals (Zacks)
Jul-07-22 10:18AM	Galmed's Aramchol Shows Anti-Fibrotic Effects In Lung Fibrosis Animal Model (Benzinga)
07:30AM	Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in a Lung Fibrosis Model (PR Newswire)
Jun-17-22 04:15PM	Galmed Pharmaceuticals Announces Receipt of Nasdaq Minimum Bid Price Notification (PR Newswire) +6.38%
Jun-15-22 10:47AM	Evotec (EVO) Inks Drug Discovery Collaboration Deal With J&J (Zacks) -8.35%
May-17-22 08:00AM	Galmed Pharmaceuticals Reports First Quarter 2022 Financial Results (PR Newswire)
07:30AM	Galmed updates business and clinical development strategy to better leverage Aramchol's anti-fibrotic effects (PR Newswire)
May-02-22 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Fourth Quarter and Year End 2021 Financial Results (PR Newswire) -26.51%
Apr-28-22 07:00AM	Galmed reports interim results from the Open-Label part of the ARMOR study with Aramchol showing robust fibrosis improvement across multimodality histological assessment (PR Newswire)
Apr-26-22 08:30AM	Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2021 Financial Results and Provide Business Update on Monday May 2 (PR Newswire)
Mar-29-22 10:18AM	These 10 Penny Stocks are Trending on Reddit (Insider Monkey)
Jan-11-22 07:30AM	Galmed Continues to Drive Innovation with Three New US Patents Granted for Aramchol and its Meglumine Salt (PR Newswire)
Jan-10-22 07:30AM	Galmed announces positive results of Phase 1 study of Amilo-5MER (PR Newswire) -13.53%
Nov-08-21 07:30AM	Galmed Pharmaceuticals Provides Additional Positive Data from the Open Label Part of ARMOR Study and Reports Third Quarter 2021 Financial Results (PR Newswire) +6.79%
07:00AM	Galmed Announces New Positive Data from Ongoing ARMOR Study Open Label Part Showing Clinically Significant Effect on Fibrosis Improvement (PR Newswire)
Nov-01-21 12:38PM	Galmed Reveals Early Aramchol Data From Late-Stage NASH Trial (Benzinga) +15.38%
10:10AM	Galmed Announces Positive Results from First 16 Patients in Open-Label Part of ARMOR Study (PR Newswire)
Oct-11-21 08:00AM	Results of Galmed's Phase 2b ARREST Trial of Aramchol Published in Nature Medicine (PR Newswire)
Aug-24-21 12:03PM	Trillium (TRIL) to be Acquired by Pfizer for $2.3 Billion (Zacks) +10.42%
Aug-19-21 11:49AM	Galmed's Anti-Inflammatory Compound Shows Encouraging Preclinical Action (Benzinga) +5.84%
08:00AM	Galmed Pharmaceuticals Announces Publication in "The Journal of Autoimmunity" for its IND ready, Amilo-5MER, a specific anti-inflammatory compound (PR Newswire)
Aug-16-21 08:00AM	MHRA Agrees with Galmed's Plan to use Aramchol meglumine in the Randomized Double-blind Placebo-Controlled Part of the Phase 3 ARMOR study (PR Newswire) -7.80%
Aug-11-21 12:48PM	Catalyst (CPRX) Up More Than 20% in Past 3 Months: Here's Why (Zacks)
Aug-10-21 03:41PM	Catalyst (CPRX) Q2 Earnings Top Estimates, Revenues Rise Y/Y (Zacks)
Aug-05-21 07:00AM	Galmed Pharmaceuticals Provides Business Update and Reports Second Quarter 2021 Financial Results (PR Newswire)
Aug-03-21 04:49AM	We Think Galmed Pharmaceuticals (NASDAQ:GLMD) Needs To Drive Business Growth Carefully (Simply Wall St.)
Aug-02-21 09:26AM	Galmed Stock Jumps As FDA Signs Off Use Of Aramchol Meglumine In Late Stage NASH Trial (Benzinga) +17.27%
07:30AM	FDA Agrees with Galmed's Plan to use Aramchol Meglumine in the Randomized Double-Blind Placebo-Controlled Part of the Phase 3 ARMOR study (PR Newswire)
Jul-29-21 08:30AM	Galmed Pharmaceuticals to Report Second Quarter 2021 Financial Results and Provide Business Update on Thursday August 5 (PR Newswire)
Jun-04-21 06:57AM	Why Is Penny Stock Galmed Pharma A Strong Buy With Triple-Digit Upside? (TipRanks) +24.09%
May-13-21 07:50AM	Galmed Pharmaceuticals Provides Business Updates and Reports First Quarter 2021 Financial Results (PR Newswire) -8.20%
06:30AM	Galmed Pharmaceuticals Ltd. to Host Earnings Call (ACCESSWIRE)

Show Previous News

Eocene Ltd. is a clinical-stage drug development biopharmaceutical company, which engages in the development of oral therapy for the treatment of non-alcoholic steato-hepatitis (NASH). Its product candidate, Aramchol, is a synthetic fatty acid-bile acid conjugate molecule for the oral treatment of NASH in patients who are overweight or obese and have prediabetes or type II diabetes mellitus. The company was founded by Allen Baharaff and Tuvia Gilat in 2000 and is headquartered in Tel Aviv, Israel.

Co-FounderMr. Allen Baharaff

Chief Financial OfficerMr. Doron Cohen

COO & Data Protection OfficerMr. Guy Nehemya

Chief Accounting OfficerMr. Yohai Stenzler CPA

Ph.D.Dr. Liat Hayardeny MBA

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

EOCN

Eocene Ltd

Upgrade your Finviz experience